Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 182

1.

Impact of adjuvant chemotherapy in completely resected stage IIIA non-small cell lung cancer.

Naim Younes R, Gross JL, Abrao FG, Rodrigues Pereira J.

Minerva Chir. 2013 Apr;68(2):169-74. Review.

PMID:
23612230
2.

Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.

Kumar P, Herndon J 2nd, Langer M, Kohman LJ, Elias AD, Kass FC, Eaton WL, Seagren SL, Green MR, Sugarbaker DJ.

Cancer. 1996 Jun 1;77(11):2393-9.

3.

Adjuvant Chemotherapy in Resected Stage II Non-small Cell Lung Cancer: Evaluating the Impact of Dose Intensity and Time to Treatment.

Ramsden K, Laskin J, Ho C.

Clin Oncol (R Coll Radiol). 2015 Jul;27(7):394-400. doi: 10.1016/j.clon.2015.03.001. Epub 2015 Mar 19.

PMID:
25800720
4.

Postoperative adjuvant chemotherapy and radiotherapy for stage II and III non-small cell lung cancer (NSCLC).

Lee SW, Choi EK, Chung WK, Shin KH, Ahn SD, Kim JH, Kim SW, Suh C, Lee JS, Kim WS, Kim DS, Kim DK, Park SI, Sohn KH.

Lung Cancer. 2002 Jul;37(1):65-71.

PMID:
12057869
5.

Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901.

Garrido P, González-Larriba JL, Insa A, Provencio M, Torres A, Isla D, Sanchez JM, Cardenal F, Domine M, Barcelo JR, Tarrazona V, Varela A, Aguilo R, Astudillo J, Muguruza I, Artal A, Hernando-Trancho F, Massuti B, Sanchez-Ronco M, Rosell R.

J Clin Oncol. 2007 Oct 20;25(30):4736-42.

PMID:
17947721
6.

Treatment Patterns and Health Resource Utilization Among Patients Diagnosed With Early Stage Resected Non-Small Cell Lung Cancer at US Community Oncology Practices.

Buck PO, Saverno KR, Miller PJ, Arondekar B, Walker MS.

Clin Lung Cancer. 2015 Nov;16(6):486-95. doi: 10.1016/j.cllc.2014.12.010. Epub 2014 Dec 31.

7.

Evaluation of the safety and compliance of 3-week cycles of vinorelbine on days 1 and 8 and cisplatin on day 1 as adjuvant chemotherapy in Japanese patients with completely resected pathological stage IB to IIIA non-small cell lung cancer: a retrospective study.

Shukuya T, Takahashi T, Tamiya A, Ono A, Igawa S, Tsuya A, Nakamura Y, Murakami H, Naito T, Kaira K, Endo M, Yamamoto N.

Jpn J Clin Oncol. 2009 Mar;39(3):158-62. doi: 10.1093/jjco/hyn147. Epub 2009 Jan 12.

PMID:
19139038
8.

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.

Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzáles-Larriba JL, Grodzki T, Pereira JR, Le Groumellec A, Lorusso V, Clary C, Torres AJ, Dahabreh J, Souquet PJ, Astudillo J, Fournel P, Artal-Cortes A, Jassem J, Koubkova L, His P, Riggi M, Hurteloup P.

Lancet Oncol. 2006 Sep;7(9):719-27. Erratum in: Lancet Oncol. 2006 Oct;7(10):797.

PMID:
16945766
9.

Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer.

Yan D, Wei P, An G, Chen W.

J Cardiothorac Surg. 2013 Jun 10;8:149. doi: 10.1186/1749-8090-8-149.

10.

[Adjuvant chemotherapy for non-small cell lung cancer].

Okamoto T, Ichinose Y.

Gan To Kagaku Ryoho. 2006 Dec;33(13):1985-90. Review. Japanese.

PMID:
17197740
11.

Adjuvant chemotherapy for early-stage non-small-cell lung cancer. Single-centre experience and literature review.

Custodio Carretero AB, García Sáenz JA, González Larriba JL, Bobokova J, Calles Blanco A, Hernando Trancho F, García Paredes B, Rodríguez Lajusticia L, Díaz-Rubio García E.

Clin Transl Oncol. 2008 Sep;10(9):560-71.

PMID:
18796373
12.

Cisplatin plus gemcitabine as adjuvant chemotherapy for radically resected non-small-cell lung cancer: a pilot study.

Tibaldi C, Mazzoni E, Arcabasso G, D'Incecco A, Antonuzzo A, Menconi G, Falcone A.

Clin Lung Cancer. 2009 Jan;10(1):53-7. doi: 10.3816/CLC.2009.n.008.

PMID:
19289373
13.

Phase II study of adjuvant vinorelbine and cisplatin in Japanese patients with completely resected stage II and III non-small cell lung cancer.

Sonobe M, Okubo K, Teramukai S, Yanagihara K, Sato M, Sato T, Chen F, Sato K, Fujinaga T, Shoji T, Omasa M, Sakai H, Miyahara R, Bando T, Date H.

Cancer Chemother Pharmacol. 2014 Dec;74(6):1199-206. doi: 10.1007/s00280-014-2595-5. Epub 2014 Sep 25.

PMID:
25253046
14.

Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial.

Douillard JY, Rosell R, De Lena M, Riggi M, Hurteloup P, Mahe MA; Adjuvant Navelbine International Trialist Association.

Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):695-701. doi: 10.1016/j.ijrobp.2008.01.044. Epub 2008 Apr 24.

PMID:
18439766
15.

Use of Adjuvant Cisplatin-Based Versus Carboplatin-Based Chemotherapy in Non-Small-Cell Lung Cancer: Findings From the Florida Initiative for Quality Cancer Care.

Tanvetyanon T, Lee JH, Fulp WJ, Schreiber F, Brown RH, Levine RM, Cartwright TH, Abesada-Terk G, Kim GP, Alemany C, Faig D, Sharp PV, Markham MJ, Malafa M, Jacobsen PB.

J Oncol Pract. 2015 Jul;11(4):332-7. doi: 10.1200/JOP.2014.001750. Epub 2015 May 19.

PMID:
25991639
16.

Postoperative adjuvant therapy for stage II non-small-cell lung cancer.

Park JH, Shim YM, Baek HJ, Kim MS, Choe DH, Cho KJ, Lee CT, Zo JI.

Ann Thorac Surg. 1999 Nov;68(5):1821-6.

PMID:
10585065
17.

A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin.

Chang WJ, Sun JM, Lee JY, Ahn JS, Ahn MJ, Park K.

Lung Cancer. 2014 Apr;84(1):51-5. doi: 10.1016/j.lungcan.2014.01.017. Epub 2014 Jan 28.

PMID:
24521819
18.

Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer.

Park SY, Lee JG, Kim J, Byun GE, Bae MK, Lee CY, Kim DJ, Chung KY.

J Cardiothorac Surg. 2013 Jun 11;8:151. doi: 10.1186/1749-8090-8-151.

19.

[A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIa non-small-cell lung cancer].

Noël G, Mazeron JJ.

Cancer Radiother. 2001 Apr;5(2):195-6. French. No abstract available.

PMID:
11355584
20.

Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer.

Scagliotti GV, Fossati R, Torri V, Crinò L, Giaccone G, Silvano G, Martelli M, Clerici M, Cognetti F, Tonato M; Adjuvant Lung Project Italy/European Organisation for Research Treatment of Cancer-Lung Cancer Cooperative Group Investigators.

J Natl Cancer Inst. 2003 Oct 1;95(19):1453-61.

PMID:
14519751

Supplemental Content

Support Center